Key facts
- Notable investors include Furong Capital, Hebei Coastal Industry Investment Fund, Duce Capital, Finnova Capital, Ningbo Junan Holdings — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for AstaThera
- ·The full record, as it builds
Funding rounds
No funding rounds for AstaThera are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AstaThera
Developer of radionuclide therapies and diagnostic and therapeutic radionuclide drugs intended for industry users and patients. The company focuses on the research and development of integrated diagnostic and therapeutic radionuclide drugs, using alpha radionuclide production and labeling technology, providing clients with a variety of innovative and effective treatments.
- Sector
- Healthcare
- HQ
- Ningbo, China
- Founded
- 2020
- Website
- astathera.com/
- Ownership
- Privately Held (backing)
AstaThera doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AstaThera shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AstaThera in its N-PORT filings yet. We sweep new filings monthly.